(Q37702244)

22 August 2017

1 reference

title

New evidence on pitavastatin: efficacy and safety in clinical studies (English)

1 reference

22 August 2017

Tamio Teramoto

1

1 reference

22 August 2017

Hitoshi Shimano

series ordinal

2

1 reference

22 August 2017

Koutaro Yokote

series ordinal

3

1 reference

22 August 2017

Mitsuyoshi Urashima

series ordinal

4

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 April 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

published in

1 reference

22 August 2017

volume

11

1 reference

22 August 2017

issue

5

1 reference

22 August 2017

page(s)

817-828

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Pitavastatin: efficacy and safety in intensive lipid lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis pr

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-dens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Combined cardiovascular risk factors and outcome: NIPPON DATA80, 1980-1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Pharmacokinetic, pharmacodynamic, and safety profile of a new cholesteryl ester transfer protein inhibitor in healthy human subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow-up study in the Japanese general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Drug-drug interaction between pitavastatin and various drugs via OATP1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Statin therapy and risk of developing type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology intravascular ultrasound.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003641990

10.1517/14656561003641990

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference